Clinical trial · Observational
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy. It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial carcinoma * Age \> 18 years * Hemoglobin \> 10g/dl * Signed Informed Consent * Karnofsky index \< 70% Exclusion Criteria: * Clinically relevant second malignancy * Severe comorbidities (e.g. NYHA III, end-stage renal disease) * Chronic infectious disease (HIV, Tuberculosis) * Immunosupression * Severe psychiatric diseases * Blood donation in the last 4 weeks
References
Publications (0)
Data not yet available